Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
- Conditions
- Obesity
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1507
- Registration Number
- NCT00386061
- Locations
- 🇸🇪
Sanofi-Aventis, Bromma, Sweden
Bioavailability of the Fixed Combination of Amodiaquine and Artesunate Under Fed & Fasted Conditions
- Conditions
- Malaria
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2008-12-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 22
- Registration Number
- NCT00386503
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2010-02-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1110
- Registration Number
- NCT00386191
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-10-09
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 680
- Registration Number
- NCT00385307
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Study of Valproate in Young Patients Suffering From Epilepsy
- First Posted Date
- 2006-10-09
- Last Posted Date
- 2009-10-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 81
- Registration Number
- NCT00385411
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 352
- Registration Number
- NCT00384215
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Insulin Glargine "All to Target" Trial
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 588
- Registration Number
- NCT00384085
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Docetaxel and Oxaliplatin in Gastric Cancer
- Conditions
- Stomach Neoplasms
- Interventions
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 275
- Registration Number
- NCT00382720
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Topic Compatibility Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene
- Conditions
- Hygiene
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT00380991
- Locations
- 🇧🇷
Sanofi-aventis, São Paulo, Brazil
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
- Conditions
- Alzheimer Disease
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 162
- Registration Number
- NCT00380302
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden